ProBioGen and Mapp Partner on Antibody for Marburg Virus

Aim to address the urgent need for advanced therapies against MARV infections, a severe and often fatal illness caused by the Marburg virus.

Author Image

By: Charlie Sternberg

Associate Editor

ProBioGen, a CDMO of solutions and services for biopharmaceutical development, has partnered with Mapp Biopharmaceutical Inc. to develop a cell line for an afucosylated antibody targeting Marburg virus (MARV) infection. This collaborative effort will leverage ProBioGen’s GlymaxX technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.   Under the terms of the agreement, ProBioGen will contribute its expertise in cell line development includin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters